Mild traumatic brain injury (mTBI) can be associated with a number of neurosensory sequelae. While a number of these can be mild and self-limited, some individuals who suffer from mTBI may have a significant period of diminished function with long-lasting consequences. In addition, there is mounting evidence that long-term chronic brain dysfunction may occur in some of those who suffer even a mild injury. Effective treatments for mTBI could reduce the period of initial disability and protect against long-term consequences. Despite this motivation there has been a little change in the treatment of mTBI for many years. However, as a result of an increase in both public and scientific interests in mTBI, there are a number of new therapies on the horizon. Many of these are in the early (preclinical) stage of development, while others have already undergone successful clinical trials. This chapter reviews the next generation of medicines and therapies that may prove useful in treating mTBI.
|Original language||English (US)|
|Title of host publication||Neurosensory Disorders in Mild Traumatic Brain Injury|
|Number of pages||12|
|State||Published - Jan 1 2019|
- Medical treatment
ASJC Scopus subject areas